Skip to content

The effectiveness of Genicular nerve infiltration versus peri-articular injection in total knee replacement

The effectiveness of Genicular nerve infiltration versus peri-articular injection in total knee replacement

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230628006
Enrollment
180
Registered
2023-06-28
Start date
2021-04-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic knee pain in patients who have a diagnosis of knee osteoarthritis, underwent simultaneous total knee arthroplasty Genicular nerve infiltration Periarticular injection Total knee arthroplasty Total knee replacement

Interventions

Standard total knee arthroplasty without intraoperative local anesthetic injection,Standard total knee arthroplasty with intraoperative anesthetic injection with 0.5% bupivacaine 20 ml dilute in 0.9%
Control group,Periarticular injection (PAI),Genicular infiltration

Sponsors

Nakornping Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: patients who underwent simultaneous unilateral and bilateral total knee arthroplasty (TKA)

Exclusion criteria

Exclusion criteria: Contraindication for total knee arthroplasty from Thai OA knee guideline 2011 contra-indication for spinal anesthesia cognitive impairment patient Chronic renal disease (Creatinine clearance < 30 ml/min) Patients who are chronic alcohol users (defined as >1 drink per night for women or >2 drinks per night for men) Patients with poorly controlled diabetes mellitus (HbA1C >7.5 on preadmission testing) Patients with steroid or immunosuppressive drug use within 6 months of surgery Severe heart and liver disease Preoperative history of venous thromboembolism or deep vein thrombosis Patients with a hypercoagulable disorder Patients with a concurrent physical condition that may require analgesic treatment during study follow-up Allergy to drugs in the study chronic opioid used

Design outcomes

Primary

MeasureTime frame
Visual analog pain score 4, 24, 48 hours, 2 weeks and 6 weeks postoperatively point/ ask patient give pain score in scale 0-10 point while they rest and on motion

Secondary

MeasureTime frame
extra dose opioid 24, 48 hours postoperatively miligram/ record from PCA chart,Time to first dose opioid 24 hours hours/ time zero is immediate post op to time that patient request IV opioid (while pain score more than 3),Length of stay 5 days days /time from admission to discharge,modified Thai WOMAC score 1 day before operation, 2 and 6 weeks after operation point/ ask patient and record in modified Thai WOMAC score chart then sum total score,Range of motion 1 day before operation, 24,48 hours, 2 and 6 weeks after operation degree/ used goniometer to measure range of motion from maximum extension to flexion

Countries

Thailand

Contacts

Public ContactApisit Aoimoon

Nakornping Hospital

apisitaoimoon@gmail.com0819606755

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026